Variations in pediatric hospitalization rates: why do they occur?

J. Perrin

DOI: https://doi.org/10.3928/0090-4481-19941201-08

1994-12-01

Pediatric Annals

Abstract:

What problem does this paper attempt to address?

Acute decompensated pulmonary hypertension

Laurent Savale,Jason Weatherald,Xavier Jaïs,Constance Vuillard,Athénaïs Boucly,Mitja Jevnikar,David Montani,Olaf Mercier,Gerald Simonneau,Elie Fadel,Olivier Sitbon,Marc Humbert

DOI: https://doi.org/10.1183/16000617.0092-2017

2017-11-15

Abstract:Acute right heart failure in chronic precapillary pulmonary hypertension is characterised by a rapidly progressive syndrome with systemic congestion resulting from impaired right ventricular filling and/or reduced right ventricular flow output. This clinical picture results from an imbalance between the afterload imposed on the right ventricle and its adaptation capacity. Acute decompensated pulmonary hypertension is associated with a very poor prognosis in the short term. Despite its major impact on survival, its optimal management remains very challenging for specialised centres, without specific recommendations. Identification of trigger factors, optimisation of fluid volume and pharmacological support to improve right ventricular function and perfusion pressure are the main therapeutic areas to consider in order to improve clinical condition. At the same time, specific management of pulmonary hypertension according to the aetiology is mandatory to reduce right ventricular afterload. Over the past decade, the development of extracorporeal life support in refractory right heart failure combined with urgent transplantation has probably contributed to a significant improvement in survival for selected patients. However, there remains a considerable need for further research in this field.
Clinicopathologic conference; polycystic kidneys with generalized osteitis fibrosa cystica and parathyroid hyperplasia.

R. H. Turner,E. Farber,J. V. Hopkins

1952-03-01

Abstract:
Approach to Decompensated Right Heart Failure in the Acute Setting

Catherine V. Levitt,Caitlin A. Williams,Jalil Ahari,Ali Pourmand

DOI: https://doi.org/10.3390/jcm13030869

IF: 3.9

2024-02-03

Journal of Clinical Medicine

Abstract:Acute right heart failure (ARHF) arises when the right ventricle fails to pump blood efficiently to the pulmonary circulation. This inefficiency leads to a decreased blood supply to various organs. ARHF is a significant health concern, often leading to increased hospital admissions and being associated with a higher risk of mortality. This condition underscores the importance of effective cardiac care and timely intervention to manage its complications and improve patient outcomes. Diagnosing ARHF involves a comprehensive approach that includes a physical examination to evaluate the patient's fluid status and heart-lung function, blood tests to identify potential triggers and help forecast patient outcomes and various imaging techniques. These imaging techniques include electrocardiograms, point-of-care ultrasounds, computed tomography, cardiac magnetic resonance imaging, and other advanced monitoring methods. These diagnostic tools collectively aid in a detailed assessment of the patient's cardiac and pulmonary health, essential for effective management of ARHF. The management of ARHF focuses on addressing the underlying causes, regulating fluid balance, and enhancing cardiac function through pharmacological treatments or mechanical support aimed at boosting right heart performance. This management strategy includes the use of medications that modulate preload, afterload, and inotropy; vasopressors; anti-arrhythmic drugs; ensuring proper oxygenation and ventilation; and the utilization of heart and lung assist devices as a bridge to potential transplantation. This review article is dedicated to exploring the pathophysiology of ARHF, examining its associated morbidity and mortality, evaluating the various diagnostic tools available, and discussing the diverse treatment modalities. The article seeks to provide a comprehensive understanding of ARHF, its impact on health, and the current strategies for its management.

medicine, general & internal
Pulmonary hypertension in the intensive care unit. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK

Michael Kaestner,Dietmar Schranz,Gregor Warnecke,Christian Apitz,Georg Hansmann,Oliver Miera

DOI: https://doi.org/10.1136/heartjnl-2015-307774

IF: 5.7

2016-04-06

Heart

Abstract:Acute pulmonary hypertension (PH) complicates the course of several cardiovascular, pulmonary and other systemic diseases in children. An acute rise of RV afterload, either as exacerbating chronic PH of different aetiologies (eg, idiopathic pulmonary arterial hypertension (PAH), chronic lung or congenital heart disease), or pulmonary hypertensive crisis after corrective surgery for congenital heart disease, may lead to severe circulatory compromise. Only few clinical studies provide evidence on how to best treat children with acute severe PH and decompensated RV function, that is, acute RV failure. The specific treatment in the intensive care unit should be based on the underlying pathophysiology and not only be focused on so-called 'specific' or 'tailored' drug therapy to lower RV afterload. In addition therapeutic efforts should aim to optimise RV preload, and to achieve adequate myocardial perfusion, and cardiac output. Early recognition of patients at high risk and timely initiation of appropriate therapeutic measures may prevent the development of severe cardiac dysfunction and low cardiac output. In patients not responding adequately to pharmacotherapy, (1) novel surgical and interventional techniques, temporary mechanical circulatory support with extracorporeal membrane oxygenation, (2) pumpless lung assist devices (3) and/or lung or heart-lung transplantation should be timely considered. The invasive therapeutic measures can be applied in a bridge-to-recovery or bridge-to-lung transplant strategy. This consensus statement focuses on the management of acute severe PH in the paediatric intensive care unit and provides an according treatment algorithm for clinical practice.

cardiac & cardiovascular systems
[Decompensated right heart failure, intensive care and perioperative management in patients with pulmonary hypertension]

K M Olsson,M Halank,B Egenlauf,D Fistera,H Gall,C Kaehler,K Kortmann,T Kramm,M Lichtblau,A Marra,C Nagel,A Sablotzki,H-J Seyfarth,D Schranz,S Ulrich,M M Hoeper,T J Lange

DOI: https://doi.org/10.1055/s-0042-114527

Abstract:The 2015 European Guidelines on Diagnosis and Treatment of Pulmonary Hypertension are also valid for Germany. The guidelines contain detailed recommendations for the targeted treatment of pulmonary arterial hypertension (PAH). However, the practical implementation of the European Guidelines in Germany requires the consideration of several country-specific issues and already existing novel data. This requires a detailed commentary to the guidelines, and in some aspects an update already appears necessary. In June 2016, a Consensus Conference organized by the PH working groups of the German Society of Cardiology (DGK), the German Society of Respiratory Medicine (DGP) and the German Society of Pediatric Cardiology (DGPK) was held in Cologne, Germany. This conference aimed to solve practical and controversial issues surrounding the implementation of the European Guidelines in Germany. To this end, a number of working groups was initiated, one of which was specifically dedicated to the management of decompensated right heart failure, intensive care management and perioperative management in patients with pulmonary hypertension. This article summarizes the results and recommendations of the working group on decompensated right heart failure, intensive care and perioperative management in patients with pulmonary hypertension.
Transplantation, bridging, and support technologies in pulmonary hypertension

Laurent Savale,Alberto Benazzo,Paul Corris,Shaf Keshavjee,Deborah Jo Levine,Olaf Mercier,R Duane Davis,John T Granton

DOI: https://doi.org/10.1183/13993003.01193-2024

2024-08-29

Abstract:Despite the progress made in medical therapies for treating pulmonary hypertension (PH), a subset of patients remain susceptible to developing a maladaptive right ventricular phenotype. The effective management of end-stage PH presents substantial challenges, necessitating a multidisciplinary approach and early identification of patients prone to acute decompensation. Identifying potential transplant candidates and assessing the feasibility of such a procedure are pivotal tasks that should be undertaken early in the treatment algorithm. Inclusion on the transplant list is contingent upon a comprehensive risk assessment, also considering the specific type of PH and various factors affecting waiting times, all of which should inform the decision-making process. While bilateral lung transplantation is the preferred option, it demands expert intra- and post-operative management to mitigate the heightened risks of pulmonary oedema and primary graft dysfunction in PH patients.Despite the availability of risk assessment tools, the occurrence of acute PH decompensation episodes can be unpredictable, potentially leading to refractory right ventricular failure even with optimal medical intervention, necessitating the use of rescue therapies. Advancements in right ventricular assist techniques and adjustments to graft allocation protocols for the most critically ill patients have significantly enhanced the survival in intensive care, affording the opportunity to endure while awaiting an urgent transplant. Given the breadth of therapeutic options available, specialised centres capable of delivering comprehensive care have become indispensable for optimising patient outcomes. These centres are instrumental in providing holistic support and management tailored to the complex needs of PH patients, ultimately enhancing their chances of a successful transplant and improved long-term prognosis.
Pulmonary Hypertension: Pharmacological and Non-Pharmacological Therapies

Jason Tsai,Shaista Malik,Stephanie C. Tjen-A-Looi

DOI: https://doi.org/10.3390/life14101265

2024-10-06

Life

Abstract:Pulmonary hypertension (PH) is a severe and chronic disease characterized by increased pulmonary vascular resistance and remodeling, often precipitating right-sided heart dysfunction and death. Although the condition is progressive and incurable, current therapies for the disease focus on multiple different drugs and general supportive therapies to manage symptoms and prolong survival, ranging from medications more specific to pulmonary arterial hypertension (PAH) to exercise training. Moreover, there are multiple studies exploring novel experimental drugs and therapies including unique neurostimulation, to help better manage the disease. Here, we provide a narrative review focusing on current PH treatments that target multiple underlying biochemical mechanisms, including imbalances in vasoconstrictor–vasodilator and autonomic nervous system function, inflammation, and bone morphogenic protein (BMP) signaling. We also focus on the potential of novel therapies for managing PH, focusing on multiple types of neurostimulation including acupuncture. Lastly, we also touch upon the disease's different subgroups, clinical presentations and prognosis, diagnostics, demographics, and cost.

biology
Management of the peri-intubation period in patients with pulmonary arterial hypertension and respiratory failure

Alexander I. Papolos,Benjamin B. Kenigsberg,Daniel R. Austin,Christopher F. Barnett

DOI: https://doi.org/10.1007/s11886-024-02081-y

IF: 3.955

2024-06-25

Current Cardiology Reports

Abstract:The endotracheal intubation of patients with pulmonary arterial hypertension (PAH) in respiratory distress is a highly morbid procedure that can precipitate hemodynamic collapse. Here we review our strategy for confronting this difficult clinical situation.

cardiac & cardiovascular systems
A study of metal distribution from lignite fuels using trees as biological monitors.

T. Sawidis,M. Chettri,A. Papaioannou,G. Zachariadis,J. Stratis

DOI: https://doi.org/10.1006/EESA.2000.2001

IF: 7.129

Ecotoxicology and Environmental Safety

Abstract:Concentrations of five metals (Cd, Cu, Mn, Fe, Zn) were determined in tree leaves collected from an area with large coal-fired plants in Ptolemais, Macedonia, Greece. The analyses were carried out with flame atomic absorption spectroscopy. Mean heavy metal content in the tree leaves is, in descending order, Fe>Mn>Zn>Cu>Cd. In Populus nigra and Salix babylonica the dense piled leaves and the widespread root system are the reasons for high heavy metal uptake. Conifer trees Pinus nigra and Juniperus arizona, which have a rough leaf surface, also had elevated concentrations. Leaves with a smooth surface were less contaminated. The presence of one metal within leaf cells may reduce the uptake or toxicity of other metals. Fruits accumulated less heavy metal than the corresponding leaves. The most damaged areas are those in the direct vicinity of the coal power plants, and the rate of damage caused in the environment is affected by the main wind direction. All sampling sites in Ptolemais basin are generally more or less polluted when compared with the control site.
Pulmonary Hypertension in Adult Congenital Heart Disease–Related Heart Failure

Jonathan Kusner,Richard A. Krasuski

DOI: https://doi.org/10.1016/j.hfc.2023.12.010

IF: 3.4

2024-03-10

Heart Failure Clinics

Abstract:• Elevated pulmonary vascular resistance (PVR) in the setting of adult congenital heart disease (ACHD) complicated by heart failure (HF) requires careful assessment of pulmonary and systemic flows. • In the setting of HF, the initiation of pulmonary vasodilators can only occur safely in a closely monitored setting. • Managing elevated PVRs in the setting of ACHD-HF uses medical, interventional, and surgical techniques that must be considered by a multidisciplinary management team. Elevated pulmonary vascular resistance (PVR) in the setting of adult congenital heart disease (ACHD) complicated by heart failure (HF) requires careful assessment of pulmonary and systemic flows. In the setting of HF, the initiation of pulmonary vasodilators can only occur safely in a closely monitored setting. Managing elevated PVRs in the setting of ACHD-HF uses medical, interventional, and surgical techniques that must be considered by a multidisciplinary management team.

cardiac & cardiovascular systems
Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review.

N. Ruopp,B. Cockrill

DOI: https://doi.org/10.1001/jama.2022.4402

2022-04-12

Abstract:Importance Pulmonary arterial hypertension (PAH) is a subtype of pulmonary hypertension (PH), characterized by pulmonary arterial remodeling. The prevalence of PAH is approximately 10.6 cases per 1 million adults in the US. Untreated, PAH progresses to right heart failure and death. Observations Pulmonary hypertension is defined by a mean pulmonary artery pressure greater than 20 mm Hg and is classified into 5 clinical groups based on etiology, pathophysiology, and treatment. Pulmonary arterial hypertension is 1 of the 5 groups of PH and is hemodynamically defined by right heart catheterization demonstrating a mean pulmonary artery pressure greater than 20 mm Hg, a pulmonary artery wedge pressure of 15 mm Hg or lower, and a pulmonary vascular resistance of 3 Wood units or greater. Pulmonary arterial hypertension is further divided into subgroups based on underlying etiology, consisting of idiopathic PAH, heritable PAH, drug- and toxin-associated PAH, pulmonary veno-occlusive disease, PAH in long-term responders to calcium channel blockers, and persistent PH of the newborn, as well as PAH associated with other medical conditions including connective tissue disease, HIV, and congenital heart disease. Early presenting symptoms are nonspecific and typically consist of dyspnea on exertion and fatigue. Currently approved therapy for PAH consists of drugs that enhance the nitric oxide-cyclic guanosine monophosphate biological pathway (sildenafil, tadalafil, or riociguat), prostacyclin pathway agonists (epoprostenol or treprostinil), and endothelin pathway antagonists (bosentan and ambrisentan). With these PAH-specific therapies, 5-year survival has improved from 34% in 1991 to more than 60% in 2015. Current treatment consists of combination drug therapy that targets more than 1 biological pathway, such as the nitric oxide-cyclic guanosine monophosphate and endothelin pathways (eg, ambrisentan and tadalafil), and has shown demonstrable improvement in morbidity and mortality compared with the previous conventional single-pathway targeted monotherapy. Conclusions and Relevance Pulmonary arterial hypertension affects an estimated 10.6 per 1 million adults in the US and, without treatment, typically progresses to right heart failure and death. First-line therapy with drug combinations that target multiple biological pathways are associated with improved survival.

Medicine
Seasonal variations in susceptibility to DDT of Anopheles maculipennis in Iran.

J. de Zulueta,P. Jolivet,K. Thymakis,P. Caprari

IF: 13.831

Bulletin of the World Health Organization

Abstract:In view of the rapid development of the cities of the interior, and of the difficulties faced by some areas in jumping from the oxcart to the airplane age, few schools have adequate installations in such places. They generally use adapted buildings which present many material difficulties for remodelling into satisfactory accommodation. Small improvements have been made, however, in order to make schoolchildren conscious of sanitary principles. Provisions are made to protect tha water supply and to instal sanitary privies and toilets. Water-filtering devices are provided and the students are instructed to use individual drinking cups. School desks, benches and the blackboard are placed so as to provide good lighting.
The Conotruncus: I. Its Normal Inversion and Conus Absorption

M. Lev

DOI: https://doi.org/10.1161/01.CIR.46.3.634

IF: 37.8

1972-09-01

Circulation

Abstract:measurements to the nearest millisecond may well imply unjustified precision when using a recording paper speed of 100 mm/sec and time lines of 10 msec, but it is unlikely that the precision of our data would be enhanced by measuring to the nearest 5 msec on paper with 20 msec time lines, as recommended by Weissler and co-workers,1 or to the nearest 5 msec on paper with 40 msec time lines, as reported by Aronow et al.2 The STIs obtained immediately following exercise were corrected for heart rate using regression equations developed in resting supine subjects.1 3 Such an approach has been used by other workers in this field,4 and it is our opinion that such corrections would at least partially neutralize the chronotropic effects of exercise and better expose other exercise-related hemodynamic alterations. Although we concur with Dr. Weissler that it would have been preferable to apply regression equations developed in supine exercising subjects, to our knowledge such data are not presently available. Furthermore, the ratio of PEP/LVET did not require heart rate correction. From the conceptual standpoint, we agree that the STIs deviate from normal in parallel with other hemodynamic parameters as quantitated by correlation coefficients. In our study, these noninvasive measurements permitted the separation of a group of patients with chronic coronary artery disease (CAD) from an ageand sexmatched group of normal subjects, the former group having a significantly longer PEPC, shorter LVETC, and larger PEP/LVET at rest and exercise. The abnormal STIs occurred predominantly in a subgroup of patients in the CAD group in whom significant abnormalities of strokevolume index, cardiac index, LV dP/dt, or ejection fraction existed. However, we must take issue with Dr. Weissler if he contends that the STIs reliably detect minor abnormalities of ventricular function in the individual patient with chronic CAD. Despite significant correlations in our report between the STIs and several directly measured hemodynamic parameters, the overlap in the data prevents any confident prediction of left ventricular dysfunction as conventionally defined unless the functional abnormalities are severe. For example, in our figure 2 which correlates the left ventricular ejection fraction as measured angiographically with PEP/LVET obtained immediately after exercise, a PEP/LVET of 0.30 was associated with ejection fractions varying from 0.40 to 0.90. This occurred despite the significant correlation (r -0.67; P < 0.0005) between these two variables. On the basis of our study, we are in agreement with Dr. Weissler that one should not attempt to predict from measurements of STIs such hemodynamic variables as cardiac index, stroke-volume index, left ventricular end-diastolic pressure, pulmonary artery and wedge pressures, exercise factor, or LV dP/dt, or attempt to predict the presence and extent of coronary artery disease or left ventricular asynergy as demonstrated on cineangiography. Furthermore, the available data suggest that the STIs cannot reliably separate the individual subject with normal cardiac function or normal coronary arteries from the patient with chronic CAD with mild-to-moderate left ventricular dysfunction. Yet it is in this latter group of patients rather than those with clinically more apparent abnormalities of ventricular performance that STIs might have offered the most useful contribution as a noninvasive bedside technic. If such indirectly obtained time intervals provide an imprecise potentially misleading measure of the underlying interdependent parameters of left ventricular function, then caution should be exercised in applying them in the clinical evaluation and follow-up of the individual patient with CAD.
Management of pulmonary hypertension in special conditions

Ioana R Preston,Luke S Howard,David Langleben,Mona Lichtblau,Tomas Pulido,Rogerio Souza,Karen M Olsson

DOI: https://doi.org/10.1183/13993003.01180-2024

2024-08-29

Abstract:Care of pulmonary hypertension (PH) patients in special situations requires insightful knowledge of the pathophysiology of the cardiopulmonary system and close interaction with different specialists, depending on the situation. The role of this task force was to gather knowledge about five conditions that PH patients may be faced with. These conditions are 1) perioperative care; 2) management of pregnancy; 3) medication adherence; 4) palliative care; and 5) the influence of climate on PH. Many of these aspects have not been covered by previous World Symposia on Pulmonary Hypertension. All of the above conditions are highly affected by psychological, geographical and socioeconomic factors, and share the need for adequate healthcare provision. The task force identified significant gaps in information and research in these areas. The current recommendations are based on detailed literature search and expert opinion. The task force calls for further studies and research to better understand and address the special circumstances that PH patients may encounter.
Management of Right Ventricular Failure in Pulmonary Hypertension (and After LVAD Implantation)

Brittany Palmer,Brent Lampert,Michael A. Mathier

DOI: https://doi.org/10.1007/s11936-013-0267-0

2013-08-21

Current Treatment Options in Cardiovascular Medicine

Abstract:Opinion StatementRight ventricular failure (RVF) is increasingly recognized as a complicating feature of a number of disease states, including pulmonary arterial hypertension (PAH) and advanced heart failure. It not only contributes to symptoms and complicates management, but also dramatically impacts prognosis. In PAH, early disease detection and institution of PAH therapy can prevent or delay RVF. Once established, therapy for RVF focuses on optimizing afterload reduction with PAH therapy, controlling volume, and judiciously using inotropic support when needed. In patients undergoing implantation of a LVAD, preoperative assessment and management of RVF is critical. Risk factors for the development of RVF after LVAD have been described, and may identify a population best managed with biventricular support. Postoperative management of RVF focuses on supportive therapy, judicious use of inotropes and volume management. Ongoing research may yield insights into specific therapies to prevent or reverse RVF.
Cytotoxic compounds. XV. Reactions of the methanesulphonates of 1-arylthiopropan-2-ols and of 2-(2,4-dinitrophenylthio)propan-1-ol with nucleophiles.

M. S. Khan,L. N. Owen

DOI: https://doi.org/10.1039/P19720002067

Abstract:The products formed in the title reactions have been examined by 1H n.m.r. spectroscopy. The aryl group was p-methoxy-, p-methylthio-, p-chloro-, or 2,4-dinitro-phenyl, or phenyl, and the formation of an episulphonium intermediate is favoured by electron-donation from the aromatic ring. Solvolysis in acetic acid gives mainly the secondary acetates, the products (except those from the 2,4-dinitro-compounds) being thermodynamically controlled. With potassium acetate in acetic anhydride, approximately equal proportions of primary and secondary acetates are formed, except from the secondary 2,4-dinitro-compound, which gives 50% of 1-(2,4-dinitrophenylthio)propene. With tetramethylammonium acetate and with sodium methoxide, both 2,4-dinitro-compounds give vinyl sulphides, the other methanesulphonates yielding only mixtures of acetates or methyl ethers; the elimination reactions do not involve an intermediate episulphonium ion. Solvolysis in methanol gives mainly or entirely the secondary methyl ether, under kinetic control from the 2,4-dinitro-compounds but under varying degrees of thermodynamic control from the other methanesulphonates. An episulphonium intermediate is involved in the reactions of all the methanesulphonates with lithium bromide and with sodium azide, and in the reaction of the p-methoxy-compound with sodium phenyl sulphide, mixtures of bromides, azides, or sulphides being obtained; but the p-methylthio- and the p-chloro-compounds react with sodium phenyl sulphide by direct substitution, to give single products.
Left ventricular heart failure and pulmonary hypertension

Stephan Rosenkranz,J. Simon R. Gibbs,Rolf Wachter,Teresa De Marco,Anton Vonk-Noordegraaf,Jean-Luc Vachiéry

DOI: https://doi.org/10.1093/eurheartj/ehv512

IF: 39.3

2015-10-27

European Heart Journal

Abstract:In patients with left ventricular heart failure (HF), the development of pulmonary hypertension (PH) and right ventricular (RV) dysfunction are frequent and have important impact on disease progression, morbidity, and mortality, and therefore warrant clinical attention. Pulmonary hypertension related to left heart disease (LHD) by far represents the most common form of PH, accounting for 65-80% of cases. The proper distinction between pulmonary arterial hypertension and PH-LHD may be challenging, yet it has direct therapeutic consequences. Despite recent advances in the pathophysiological understanding and clinical assessment, and adjustments in the haemodynamic definitions and classification of PH-LHD, the haemodynamic interrelations in combined post- and pre-capillary PH are complex, definitions and prognostic significance of haemodynamic variables characterizing the degree of pre-capillary PH in LHD remain suboptimal, and there are currently no evidence-based recommendations for the management of PH-LHD. Here, we highlight the prevalence and significance of PH and RV dysfunction in patients with both HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF), and provide insights into the complex pathophysiology of cardiopulmonary interaction in LHD, which may lead to the evolution from a 'left ventricular phenotype' to a 'right ventricular phenotype' across the natural history of HF. Furthermore, we propose to better define the individual phenotype of PH by integrating the clinical context, non-invasive assessment, and invasive haemodynamic variables in a structured diagnostic work-up. Finally, we challenge current definitions and diagnostic short falls, and discuss gaps in evidence, therapeutic options and the necessity for future developments in this context.

cardiac & cardiovascular systems
Medical Management of Pulmonary Arterial Hypertension: Current Approaches and Investigational Drugs

Qi Jin,Dandan Chen,Xiaochun Zhang,Feng Zhang,Dongxiang Zhong,Dawei Lin,Lihua Guan,Wenzhi Pan,Daxin Zhou,Junbo Ge

DOI: https://doi.org/10.3390/pharmaceutics15061579

IF: 6.525

2023-05-24

Pharmaceutics

Abstract:Pulmonary arterial hypertension (PAH) is a malignant pulmonary vascular syndrome characterized by a progressive increase in pulmonary vascular resistance and pulmonary arterial pressure, which eventually leads to right heart failure and even death. Although the exact mechanism of PAH is not fully understood, pulmonary vasoconstriction, vascular remodeling, immune and inflammatory responses, and thrombosis are thought to be involved in the development and progression of PAH. In the era of non-targeted agents, PAH had a very dismal prognosis with a median survival time of only 2.8 years. With the deep understanding of the pathophysiological mechanism of PAH as well as advances in drug research, PAH-specific therapeutic drugs have developed rapidly in the past 30 years, but they primarily focus on the three classical signaling pathways, namely the endothelin pathway, nitric oxide pathway, and prostacyclin pathway. These drugs dramatically improved pulmonary hemodynamics, cardiac function, exercise tolerance, quality of life, and prognosis in PAH patients, but could only reduce pulmonary arterial pressure and right ventricular afterload to a limited extent. Current targeted agents delay the progression of PAH but cannot fundamentally reverse pulmonary vascular remodeling. Through unremitting efforts, new therapeutic drugs such as sotatercept have emerged, injecting new vitality into this field. This review comprehensively summarizes the general treatments for PAH, including inotropes and vasopressors, diuretics, anticoagulants, general vasodilators, and anemia management. Additionally, this review elaborates the pharmacological properties and recent research progress of twelve specific drugs targeting three classical signaling pathways, as well as dual-, sequential triple-, and initial triple-therapy strategies based on the aforementioned targeted agents. More crucially, the search for novel therapeutic targets for PAH has never stopped, with great progress in recent years, and this review outlines the potential PAH therapeutic agents currently in the exploratory stage to provide new directions for the treatment of PAH and improve the long-term prognosis of PAH patients.

pharmacology & pharmacy
Medical Management of Right Ventricular Dysfunction in Pulmonary Arterial Hypertension

Annalisa Caputo,Silvia Papa,Giovanna Manzi,Domenico Laviola,Tommaso Recchioni,Paolo Severino,Carlo Lavalle,Viviana Maestrini,Massimo Mancone,Roberto Badagliacca,Carmine Dario Vizza

DOI: https://doi.org/10.1007/s11897-023-00612-2

Abstract:Purpose of review: The purpose of this review is to overview the most relevant and recent knowledge regarding medical management in pulmonary arterial hypertension (PAH). Recent findings: Evidence has shown that PAH patients' quality of life and prognosis depend on the capability of the RV to adapt to increased afterload and to fully recover in response to substantially reduced pulmonary vascular resistance obtained with medical therapy. Data from recent clinical studies show that more aggressive treatment strategies, especially in higher risk categories, determine larger afterload reductions, consequentially increasing the probability of achieving right heart reverse remodeling, therefore improving the patients' survival and quality of life. Remarkable progress has been observed over the past decades in the medical treatment of PAH, related to the development of drugs that target multiple biological pathways, strategies for earlier and more aggressive treatment interventions. New hopes for treatment of patients who are unable to achieve low-risk status have been derived from the phase 2 trial PULSAR and the phase 3 trial STELLAR, which show improvement in the hemodynamic status of patients treated with sotatercept on top of background therapy. Promising results are expected from several ongoing clinical trials targeting new pathways involved in the pathophysiology of PAH.
Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology

Veli-Pekka Harjola,Alexandre Mebazaa,Jelena Čelutkienė,Dominique Bettex,Hector Bueno,Ovidiu Chioncel,Maria G Crespo-Leiro,Volkmar Falk,Gerasimos Filippatos,Simon Gibbs,Adelino Leite-Moreira,Johan Lassus,Josep Masip,Christian Mueller,Wilfried Mullens,Robert Naeije,Anton Vonk Nordegraaf,John Parissis,Jillian P Riley,Arsen Ristic,Giuseppe Rosano,Alain Rudiger,Frank Ruschitzka,Petar Seferovic,Benjamin Sztrymf,Antoine Vieillard-Baron,Mehmet Birhan Yilmaz,Stavros Konstantinides

DOI: https://doi.org/10.1002/ejhf.478

Abstract:Acute right ventricular (RV) failure is a complex clinical syndrome that results from many causes. Research efforts have disproportionately focused on the failing left ventricle, but recently the need has been recognized to achieve a more comprehensive understanding of RV anatomy, physiology, and pathophysiology, and of management approaches. Right ventricular mechanics and function are altered in the setting of either pressure overload or volume overload. Failure may also result from a primary reduction of myocardial contractility owing to ischaemia, cardiomyopathy, or arrhythmia. Dysfunction leads to impaired RV filling and increased right atrial pressures. As dysfunction progresses to overt RV failure, the RV chamber becomes more spherical and tricuspid regurgitation is aggravated, a cascade leading to increasing venous congestion. Ventricular interdependence results in impaired left ventricular filling, a decrease in left ventricular stroke volume, and ultimately low cardiac output and cardiogenic shock. Identification and treatment of the underlying cause of RV failure, such as acute pulmonary embolism, acute respiratory distress syndrome, acute decompensation of chronic pulmonary hypertension, RV infarction, or arrhythmia, is the primary management strategy. Judicious fluid management, use of inotropes and vasopressors, assist devices, and a strategy focusing on RV protection for mechanical ventilation if required all play a role in the clinical care of these patients. Future research should aim to address the remaining areas of uncertainty which result from the complexity of RV haemodynamics and lack of conclusive evidence regarding RV-specific treatment approaches.

Variations in pediatric hospitalization rates: why do they occur?

Acute decompensated pulmonary hypertension

Clinicopathologic conference; polycystic kidneys with generalized osteitis fibrosa cystica and parathyroid hyperplasia.

Approach to Decompensated Right Heart Failure in the Acute Setting

Pulmonary hypertension in the intensive care unit. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK

[Decompensated right heart failure, intensive care and perioperative management in patients with pulmonary hypertension]

Transplantation, bridging, and support technologies in pulmonary hypertension

Pulmonary Hypertension: Pharmacological and Non-Pharmacological Therapies

Management of the peri-intubation period in patients with pulmonary arterial hypertension and respiratory failure

A study of metal distribution from lignite fuels using trees as biological monitors.

Pulmonary Hypertension in Adult Congenital Heart Disease–Related Heart Failure

Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review.

Seasonal variations in susceptibility to DDT of Anopheles maculipennis in Iran.

The Conotruncus: I. Its Normal Inversion and Conus Absorption

Management of pulmonary hypertension in special conditions

Management of Right Ventricular Failure in Pulmonary Hypertension (and After LVAD Implantation)

Cytotoxic compounds. XV. Reactions of the methanesulphonates of 1-arylthiopropan-2-ols and of 2-(2,4-dinitrophenylthio)propan-1-ol with nucleophiles.

Left ventricular heart failure and pulmonary hypertension

Medical Management of Pulmonary Arterial Hypertension: Current Approaches and Investigational Drugs

Medical Management of Right Ventricular Dysfunction in Pulmonary Arterial Hypertension

Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology